reports
Inogen to Report First Quarter 2024 Financial Results on May 7, 2024
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2024 financial results after the market closes on Tuesday, May 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording o...
Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 9:30 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the page on the Inogen web...
Inogen, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(...
GOLETA, Calif.--(BUSINESS WIRE)-- . (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that, effective March 4, 2024, the Compensation Committee of Inogen’s Board of Directors approved awards of restricted stock units as material inducement to Michael Bourque entering into employment with the company to serve as its Executive Vice President, Chief Financial Officer and Treasurer. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity aw...
Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)-- . (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full-year ended December 31, 2023. “I am excited for the future of Inogen. As we progress into 2024, we are focused on positioning the business for revenue growth and long-term profitability while advancing our innovation pipeline and working to bring Physio-Assist to the U.S. market,” said Kevin Smith, President and Chief Executive Officer. “We have a strong management team with...
Inogen to Report Fourth Quarter and Full Year 2023 Financial Results o...
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. To listen to a live webc...
Inogen Names Michael Bourque as New Chief Financial Officer
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (formally NYSE:CCF) now owned by KKR & Co. Inc. He succeeds Interim Chief Financial Officer Mike Sergesketter, who will remain in an advisory role during the transition. Mr. Bourque has served as Chief Financial Officer and Treasurer of Chase ...
- Blair Levin
NSR Policy: FCC Upholds Prior Media Ownership Rules While Longer Term ...
Over the holidays, the FCC adopted a Report and Order completing the 2018 quadrennial review of the Commission's broadcast ownership rules, upholding its current media ownership rules with only minor modifications. In this note, we quickly review what the FCC did, the implications for investors, and the broader shifts that will eventually cause a major shift in those rules (as well as what we think investors are missing in their policy analysis of a potential Discovery/Warner/Paramount deal).
- Blair Levin
NSR Policy: Warner/Discovery/Paramount Deal: Initial Thoughts on Gover...
There are multiple news reports that Warner Bros./Discovery (WBD) and Paramount Global (PARA) are considering a merger. In this note, we provide a quick initial assessment of potential path for government approval of such a transaction.
Inogen Announces Leadership Change with the Appointment of Kevin Smith...
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Kevin Smith as Inogen’s President and Chief Executive Officer and a member of the Board of Directors, effective immediately, succeeding Nabil Shabshab. Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creat...
Inogen to Present at Upcoming Investor Conferences in November 2023
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences: Stifel 2023 Healthcare Conference on Wednesday, November 15 at 10:20 a.m. Eastern Time Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29 at 10:30 a.m. Eastern Time A live webcast and archived recording of each presentation will be available to all interested parties through the page on the Inogen website. Inogen has used, and i...
Inogen Announces Third Quarter 2023 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights Reported total revenue of $84.0 million, reflecting a decrease of 20.3% from the third quarter of 2022. Completed acquisition of Physio-Assist SAS, expanding Inogen’s global respiratory care presence by addressing a sizeable, growing, and underserved airway clearance market opportunity. “We have continued to im...
Inogen to Report Third Quarter 2023 Financial Results on November 7, 2...
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. To listen to a live webcast, please visi...
Inogen Completes Acquisition of Physio-Assist
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has completed the acquisition of Physio-Assist SAS, expanding the company’s innovative respiratory portfolio. Simeox, from Physio-Assist, is a technology-enabled airway clearance and mucus management device predominantly aimed at treating bronchiectasis which is a condition that presents as the lung’s bronchi are damaged and widened, in patients with cystic fibrosis or chronic obstructive pulmonary disease. Simeox is used in ...
Inogen Announces CFO Transition Plan
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mike Sergesketter as Interim Chief Financial Officer, effective immediately. Mr. Sergesketter last served as Interim Chief Financial Officer of the company between December 2021 and March 2022, and previously served as CFO of Kimball Electronics, Inc. where he was instrumental in helping to develop and execute the company’s globalization strategy while also building a robust finance function to s...
Inogen Recognized as a Finalist for Ragan's CSR & Diversity Awards Pro...
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it has been selected as a finalist in the Diversity, Equity & Inclusion Commitment Category for Ragan's . This recognition celebrates the outstanding efforts of organizations that have demonstrated exemplary commitment to corporate social responsibility and fostering diversity and inclusion within their communities and workplaces. The winners of Ragan's CSR & Diversity Awards will be announced during a on September 28, 202...
Inogen Announces Second Quarter 2023 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights All comparisons are to the prior year period unless otherwise noted. Reported total revenue of $83.6 million, reflecting a decrease of 19.1%; currency fluctuations accounted for 0.6% of the decrease. GAAP net loss of $9.8 million, Adjusted net loss of $5.8 million and Adjusted EBITDA loss of $3.2 million. Entered ...
Inogen Achieves Best In Class 8-Year Expected Service Life Portable Ox...
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of the Rove 6™ portable oxygen concentrator in the United States with best in class 8-year expected service life. The Inogen® Rove 6™ was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to 8 years for all Rove 6 devices sold worldwide. The 8 year best-in-class expected service life has also been extend...
Inogen Expands Its Respiratory Product Portfolio with Acquisition of P...
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company has entered into a definitive agreement to purchase Physio-Assist SAS, a privately-held company headquartered in France. Physio-Assist developed and manufactures Simeox, a technology-enabled airway clearance device with a proven efficacy and safety profile, currently used outside of the United States, to treat a condition in the lungs known as bronchiectasis, where the lung’s bronchi become damaged and widened, ...
Inogen to Present at 43rd Annual William Blair Growth Stock Conference
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in the William Blair 43rd Annual Growth Stock Conference. Nabil Shabshab, President and Chief Executive Officer, is scheduled to present on Wednesday, June 7, 2023, at 11:00 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the page on the Inogen website. Inogen has used, and intends to continue to use, its...
Inogen Announces First Quarter 2023 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights All comparisons are to the prior year period unless otherwise noted. Reported total revenue of $72.2 million, in line with company expectations, reflecting a decrease of 10.2%; currency fluctuations accounted for 1.7% of the decrease. Continued progress on rental strategy led to a 25.4% increase in rental revenue, primarily due to highe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.